In the UK, GSK and the Medical Research Council have joined forces to make the most of larger GWAS data sets, reports the UK's Business Weekly. In order to maximize the statistical potential of genome-wide association studies, the two will combine data sets and invest £1 million each over three years to focus on finding the genetic switches for two main diseases, depression and obesity. “We have worked hard to collect and refine our data but we now need to take a bold step forwards and work with others to uncover the new disease targets and genetic variations that are useful to inform drug discovery and development,” says Patrick Vallance, senior vice president Drug Discovery at GSK.
For GWAS, Collaboration is the Future
Feb 05, 2008